RSS Feeds
Current Studies on the Effect of Antimetabolites in Nephrosis, Other Non-Neoplastic Diseases, and Experimental Animals
Combined Clinical Staff Conference at the National Institutes of Health
- HOWARD C. GOODMAN, M.D.;
- SHELDON M. WOLFF, M.D.;
- ROBERT R. CARPENTER, M.D.;
- BURTON R. ANDERSEN, M.D.; and
- MICHAEL W. BRANDRISS, M.D.
- Requests for reprints should be addressed to Howard C. Goodman, M.D., National Institute of Allergy and Infectious Diseases, Bethesda 14, Maryland.
Excerpt
Dr. Howard C. Goodman: During the past 2 years, drugs which were developed for the chemotherapy of cancer and which function as antimetabolites have been administered to patients with non-neoplastic diseases. Enough remarkable remissions of these non-neoplastic diseases have occurred to indicate an interesting new development in medicine. The purpose of this conference is to review this development briefly and to present work which, although in progress, can already document both the clinical effectiveness and the toxicity of one of the purine antimetabolites, 6-thioguanine. We will also describe some experimental approaches designed to study the mechanism of action of the
Acknowledgment
Hollister-Stier Laboratories, Inc., produced the Candida albicans culture extract which Dr. Burton R. Andersen mentions.
Summario in Interlingua
Es revistate reportos in le litteratura in re le suppression, per antimetabolitos de purina, de immuno-responsas in animales e in re le production, per ille agentes, de remissiones in non-neoplastic morbos in humanos. Es reportate le toxicitate e le effecto clinic de un tal agente, i.e. 6-thioguanina (6-TG), in patientes con nephrosis, chronic hepatitis, e lupus erythematose. Le 4 patientes in le serie, le quales habeva nephrosis respondente a steroides, experientiava omnes complete remissiones como resultato del administration de 6-TG sol o de 6-TG in combination con un previemente inadequate dose de prednisona. Nulle definite remissiones occurreva in 4 patientes con nephrosis resistente contra steroides. Es describite resultatos preliminari del administration de 6-TG a patientes con chronic hepatitis e lupus erythematose. Un declino del concentration seral de immuno-globulinas sequeva le administration de 6-TG a patientes con nephrosis. Le administration de iste pharmaco produceva minus suppression de tardive reactivitate cutanee pro antigenos bacterial o mycotic que le administration de prednisona. Es discutite le effecto del administration de methotrexato in allergic encephalomyelitis experimental in porcos de India e etiam le possibile mechanismo del action del antimetabolitos.
Article and Author Information
-
This is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Maryland, by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service, Department of Health, Education, and Welfare.
-
- Received June 4, 1963.
- Accepted June 14, 1963.
